Post-earnings recap
Reported
Wed, Apr 29, 2026
EPS actual
$9.47
EPS est.
$6.28
EPS surprise
+50.70%
1-day move
-6.21%
Regeneron's strong EPS performance indicates better-than-expected profitability, which is a positive sign for investors. However, the lack of revenue data and guidance may leave some uncertainty about future performance. The stock reaction remained flat, suggesting that investors are taking a wait-and-see approach following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.47 | $8.84 | +50.70% |
| Revenue | N/A | $3.5B | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to long-term growth. However, they did not provide specific revenue figures or future guidance.
We are pleased with our EPS performance this quarter.
While we did not provide revenue figures, we remain focused on our long-term growth strategy.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and manufactures medicines for serious diseases. Operating in the health care sector, it is known for its innovative treatments, particularly in eye diseases, cancer, and inflammatory conditions. With a market cap of $79 billion, Regeneron plays a significant role in advancing medical science and improving patient outcomes.
Last quarter
In Q4-2025, Regeneron reported an EPS of $11.44, significantly exceeding estimates by 38.18%. Despite this strong performance, the stock saw a slight decline of 1.07% the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+49.12%
Avg 1-day reaction
+0.21%
Analysts expect Regeneron to report strong earnings again, with a consensus EPS of $8.84. The company has a solid track record of beating earnings expectations, which could lead to positive market reactions.
Bull case
If Regeneron continues its trend of exceeding earnings estimates, it could see a significant stock price increase, especially if revenue also comes in strong.
Bear case
Conversely, if the company fails to meet earnings expectations or if revenue growth slows, it could lead to a negative reaction in the stock price.
Key metrics to watch
EPS
$8.84Earnings per share is a key indicator of profitability and will show how well the company is performing relative to expectations.
Revenue
$3.5BRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $8.84?
Given Regeneron's history of beating EPS estimates, this will be a critical factor in determining market reaction.
Q2
What is the revenue forecast for this quarter, especially in light of recent product launches?
Revenue growth is essential for sustaining investor confidence and could significantly impact stock performance.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The consensus may underestimate Regeneron's ability to leverage its recent product launches for revenue growth, especially in the oncology segment.
Supporting evidence
Regeneron has consistently beaten EPS estimates, indicating strong operational execution.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent insider buying activity could signal confidence in upcoming results.
Key risk
If revenue growth exceeds $3.8B, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
The market is debating whether Regeneron can maintain its strong earnings momentum amid competitive pressures and market conditions.
Bull confirmed if
An EPS of $10.00 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $7.00 would confirm the bear case, suggesting potential issues in sales or cost management.
What the market is pricing for the move.
Implied Move
±7.28%
Historical Avg
±6.0%
The options market is pricing in a significant potential price movement, indicating that traders expect volatility around the earnings report.
Options are pricing ±7.1% while REGN has averaged ±6.0% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
22.6%
Smart-money positioning from the most recent 13F filings.
Institutional
93.56%
of float
Insider
2.08%
of float
Holders
1,912
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,113,506 sh · $6.8B
9.01%
1.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Regeneron beats expectations, history suggests the stock could rise by about 0.85% on the following day, confirming continued strength.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss on earnings could lead to a decline in stock price, with historical patterns suggesting an average drop of around 6.87%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
6,629,759 sh · $4.9B
6.56%
-0.4%
Dodge & Cox Inc.
4,871,137 sh · $3.6B
4.82%
9.3%
State Street Corporation
4,834,688 sh · $3.6B
4.78%
3.6%
Invesco Ltd.
3,940,665 sh · $2.9B
3.90%
0.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded May 15, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.